ArticleBMC infectious diseases2026
Response to a vaccine-derived poliovirus type 1 event - Sichuan, China, 2024.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn September 2024, a 4-month-old infant in Liangshan, Sichuan, China was diagnosed with paralytic poliomyelitis that turned out to have been caused by a vaccine-derived poliovirus type 1 (VDPV1). This was the third VDPV outbreak detected by routine acute flaccid paralysis (AFP) surveillance in Sichuan since 2012. We conducted an epidemiological investigation into the event and implemented response measures to prevent further viral spread.
methodsThe investigation and response were conducted according to World Health Organization (WHO) and China's National Health Commission standard operating procedures. Measures included case and virus verification; search for poliovirus among contacts, healthy children, and in wastewater; active surveillance for AFP cases in health facilities and communities; vaccination coverage assessment; and supplementary immunization activity (SIA) and catch-up vaccination.
resultsThe paralyzed infant was determined to be a VDPV1 case by the Sichuan provincial expert group; the VDPV1 had 10-15 nucleotide changes from Sabin strain type 1. No VDPVs were found in close contacts, healthy children, or wastewater; no AFP cases were found in health facilities or communities; no local circulation of the VDPV1 was detected. Following a county-wide SIA with catch-up vaccination, 2-dose, bivalent live attenuated polio vaccine coverage was 95.4% among children four months to four years of age, and full-series polio vaccine coverage was 98.5% in children 5-14 years of age.
conclusionsThe VDPV was an ambiguous VDPV type 1 (aVDPV1). Timely detection and response prevented further spread and development of a circulating VDPV type 1 (cVDPV1). Low vaccination coverage and poor sanitation were contributing factors to the emergence of the aVDPV1. Information technology facilitated the strategy of "Government Locates, Health Vaccinates" that rapidly raised population immunity in a low-coverage area through a high-quality SIA and interrupted spread of the virus. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.